Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ROSE: Ramucirumab + Docetaxel in HER2- Breast Cancer
NCT00703326Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2008
- Primary completion
- Mar 2013
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 23
01
Overview
A Phase 3 trial of ramucirumab in breast cancer, sponsored by Eli Lilly and Company. Started Aug 2008; status: completed.
02
Drugs
ramucirumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00703326.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00703326.